Full Papers
(
1
IR: ν
1E,3E)-N-Ethyl-4-(3-phenyl-1,2,4-oxadiazol-5-yl)buta-1,3-dien-1-amine
General Procedure for the Reaction of the Salt 9 with
2-aminopyridine and 2-(N-methylamino)-pyridine
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
1d, 0.96 g (66%), yellow crystals from ethanol, m.p. >95°C (dec.).
À 1
1
1618 cm . H-NMR (DMSO) δ: 1.12 (m, 3H, CH ); 3.47 (m,
3
C=N
A solution of the pyridinium salt 9 is prepared with 1.0 g (4.3 mmol)
in 80 mL of methanol. To this solution 2.5 equivalents of the 2-
aminopyridine and 2-(N-methylamino)-pyridine, dissolved in 20 mL
of methanol, were added dropwise. The reaction mixtures were left
under stirring at room temperature for 5 days. After this period of
time, methanol is removed at reduced pressure and the residues
were taken up with DCM. The organic phases were washed with
water and dried over anhydrous Na SO . Upon evaporation of the
2H, NÀ CH ); 5.38 (t, 1H, J=12 Hz, CH=); 5.86 (d, 1H, J=15 Hz, CH=);
2
7.08 (t, 1H, J=15 Hz, CH=); 7.17 (t, 1H, J=12 Hz, CH=); 7.54 (m, 3H,
13
phenyl); 7.98 (m, 2H, phenyl). C-NMR (DMSO) δ: 21.7; 95.0; 126.4;
27.3; 128.8; 129.2; 129.5; 147.6; 167.2; 177.4. Anal. Calcd for
C H N O (241.29): C, 69.69; H, 6.27; N, 17.41. Found: C, 69.70; H,
1
1
4
15
3
6
.25; N, 17.40.
(
1E,3E)-4-(3-Phenyl-1,2,4-oxadiazol-5-yl)-N-propylbuta-1,3-dien-1-
2
4
amine 11e, 1.38 g (90%), yellow crystals from diethylether, m.p. 82–
solvent, solid residues were submitted to chromatographic isolation
and the solid compounds were recrystallized from proper solvents
to afford the final products 12a,b that were fully characterized.
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
À 1
1
8
4°C. IR: ν
1660 cm . H-NMR (CDCl ) δ: 0.96 (t, 3H, J=7 Hz,
C
=
N
3
CH ); 1.60 (m, 2H, CH ); 3.07 (bs, 2H, J=7 Hz, NÀ CH ); 4.40 (bs, 1H,
3
2
2
NH); 5.38 (t, 1H, J=12 Hz, CH=); 6.03 (d, 1H, J=15 Hz, CH=); 6.80
(dd, 1H, J=15, 8 Hz, CH=); 7.44 (m, 3H, phenyl); 7.48 (d, 1H, J=
N-[(1E,3E)-4-(3-phenyl-1,2,4-oxadiazol-5-yl)buta-1,3-dien-1-yl]pyridin-
13
2-amine 12a, 1.19 g (95%), yellow crystals from ethanol, m.p. 184–
1
5 Hz, CH=); 8.10 (m, 2H, phenyl). C-NMR (DMSO) δ: 24.7; 45.4;
À 1
1
1
85°C. IR: ν
1647 cm . H-NMR (DMSO) δ: 6.03 (t, 1H, J=12 Hz,
9
7.3; 126.8; 127.3; 128.9; 130.9; 146.6; 148.6; 167.2; 177.3. Anal.
C=N
CH=); 6.33 (d, 1H, J=15 Hz, CH=); 6.87 (m, 2H, pyridine and CH=);
7.57 (m, 3H, phenyl); 7.65 (m, 2H, pyridine and CH=); 8.03 (m, 3H,
phenyl and pyridine); 8.21 (d, 1H, J=5 Hz, pyridine); 10.09 (d, 1H,
J=12 Hz, NH). C-NMR (DMSO) δ: 102.8; 105.1; 110.0; 116.5; 126.8;
126.9; 129.1; 131.2; 138.2; 139.0; 145.1; 148.1; 152.7; 167.6; 176.4.
Anal. Calcd for C H N O (290.32): C, 70.33; H, 4.86; N, 19.30. Found:
Calcd for C H N O (255.31): C, 70.56; H, 6.71; N, 16.46. Found: C,
15
17
3
7
0.57; H, 6.70; N, 16.44.
1
3
(
1E,3E)-N-Isopropyl-4-(3-phenyl-1,2,4-oxadiazol-5-yl)buta-1,3-dien-1-
amine 11f, 1.36 g (89%), yellow crystals from diiosopropylether,
À 1
1
m.p. 88–89°C. IR: ν
1618 cm . H-NMR (CDCl ) δ: 1.20 (d, 6H, J=
C=N
3
17 14
4
7
Hz, CH ); 3.55 (m, 1H, NÀ CH); 4.31 (m, 1H, NH); 5.38 (t, 1H, J=
C, 70.34; H, 4.87; N, 19.32.
3
12 Hz, CH=); 6.03 (d, 1H, J=15 Hz, CH=); 6.75 (dd, 1H, J=15, 8 Hz,
N-Methyl-N-[(1E,3E)-4-(3-phenyl-1,2,4-oxadiazol-5-yl)buta-1,3-dien-1-
CH=); 7.50 (m, 3H, phenyl); 7.55 (d, 1H, J=15 Hz, CH=); 8.08 (m, 2H,
13
yl]pyridin-2-amine 12b, 1.28 g (98%), yellow crystals from ethanol,
phenyl). C-NMR (DMSO) δ: 23.6; 25.2; 96.3; 126.8; 127.3; 129.0;
30.9; 147.1; 151.8; 167.3; 177.2. Anal. Calcd for C H N O (255.31):
À 1
1
m.p. 157–158°C. IR: ν
1620 cm . H-NMR (DMSO) δ: 3.38 (s, 3H,
1
C=N
15
17
3
NÀ CH ); 6.03 (t, 1H, J=12 Hz, CH=); 6.37 (d, 1H, J=15 Hz, CH=); 7.03
C, 70.56; H, 6.71; N, 16.46. Found: C, 70.55; H, 6.72; N, 16.47.
3
(dd, 1H, J=7, 6 Hz, pyridine); 7.56 (d, 1H, J=9 Hz, pyridine); 7.58
(m, 4H, phenyl and CH=); 7.77 (m, 2H, pyridine); 8.04 (m, 2H,
(
1E,3E)-N-Benzyl-4-(3-phenyl-1,2,4-oxadiazol-5-yl)buta-1,3-dien-1-
1
3
amine 11g, 1.58 g (87%), yellow crystals from ethanol, m.p. 115–
phenyl); 8.30 (d, 1H, J=12 Hz, CH=). C-NMR (DMSO) δ: 32.0; 103.5;
104.5; 109.7; 117.4; 126.8; 126.9; 129.1; 131.2; 138.6; 142.1; 145.5;
147.8; 154.4; 167.6; 176.4. Anal. Calcd for C H N O (304.35): C,
À 1
1
1
17°C. IR: ν
1646 cm . H-NMR (DMSO) δ: 4.29 (d, 1H, J=6 Hz,
C=N
NÀ CH ); 5.43 (t, 1H, J=12 Hz, CH=); 5.89 (d, 1H, J=15 Hz, CH=); 7.26
2
18 16
4
13
(
m, 7H, phenyl, CH=); 7.53 (m, 3H, phenyl); 7.97 (m, 2H, phenyl). C-
71.04; H, 5.30; N, 18.41. Found: C, 71.03; H, 5.29; N, 18.41.
NMR (DMSO) δ: 96.3; 126.8; 127.1; 127.2; 127.3; 128.5; 128.6; 128.9;
129.0; 131.0; 147.2; 167.3; 177.2. Anal. Calcd for C19 O (303.36):
H N
17 3
C, 75.23; H, 5.65; N, 13.85. Found: C, 75.25; H, 5.64; N, 13.85.
Reaction followed at the NMR Between the Pyridinium salt 9
and Dimethylamine in CD OD
3
3-Phenyl-5-[(1E,3E)-4-(pyrrolidin-1-yl)buta-1,3-dien-1-yl]-1,2,4-oxadia-
zole 11h, 1.57 g (98%), yellow crystals from methanol, m.p. 115–
1
Pyridinium salt 9 (35 mg, 0.15 mmol) was dissolved in 1 mL CD OD
3
À 1
1
16°C. IR: ν
1630 cm . H-NMR (DMSO) δ: 1.86 (bs, 4H,
and an excess dimethylmine was added. 1H NMR spectra were
recorded after 1, 6, 12 and 24 h (see Figure 4) to monitor the
reaction and evolution of intermediates and reaction products.
Similarly it was done for the reactions conducted in CDCl3.
C=N
pyrrolidine); 3.29 (bs, 4H, CH À NÀ CH pyrrolidine); 5.22 (t, 1H, J=
2
2
1
2 Hz, CH=); 5.90 (d, 1H, J=15 Hz, CH=); 7.35 (d, 1H, J=12 Hz,
13
CH=); 7.52 (m, 4H, phenyl, CH=); 7.99 (m, 2H, phenyl). C-NMR
DMSO) δ: 24.7; 96.5; 97.3; 126.8; 127.3; 129.0; 130.9; 145.7; 148.6;
167.2; 177.3. Anal. Calcd for C H N O (267.33): C, 71.89; H, 6.41; N,
(
16
17
3
15.72. Found: C, 71.90; H, 6.43; N, 15.73.
HPLC Quantitative Analyses on the Reaction Between the
Pyridinium Salt 9 and Morpholine
3
-Phenyl-5-[(1E,3E)-4-(piperidin-1-yl)buta-1,3-dien-1-yl]-1,2,4-oxadia-
zole 11i, 1.67 g (99%), yellow crystals from methanol, m.p. 88–89°C.
Pyridinium salt 9 (18 mg, 0.08 mmol) was dissolved in 25 mL CH CN
3
À 1
1
IR: νC=N 1635 cm . H-NMR (DMSO) δ: 1.54 (m, 6H, piperidine); 3.23
and 9.5 mg (0.08 mmol) of morpholine were added along with
12 mg of internal standard. The reaction was conducted at 25°C.
HPLC analyses were done at fixed times and the plot of the reaction
is reported in Figure 5.
(
m, 4H, CH À NÀ CH piperidine); 5.44 (t, 1H, J=12 Hz, CH=); 5.91 (d,
2
2
1
H, J=15 Hz, CH=); 7.10 (d, 1H, J=12 Hz, CH=); 7.53 (m, 4H, phenyl,
13
CH=); 7.99 (m, 2H, phenyl). C-NMR (DMSO) δ: 23.6; 25.2; 48.8; 95.8;
6.3; 126.8; 127.3; 128.9; 130.9; 147.1; 151.8; 167.3; 177.2. Anal.
Calcd for C H N O (281.35): C, 72.57; H, 6.81; N, 14.94. Found: C,
9
17
19
3
72.58; H, 6.82; N, 14.96.
HPLC Quantitative Analyses on the Reaction Between the
Pyridinium Salt 9 and Morpholine with and without
Norbornene at 60°C in Chloroform as Solvent
Pyridinium salt 9 (18 mg, 0.08 mmol) was dissolved in 25 mL CHCl
3
and increasing amounts of morpholine ([Morpholine/[9]=3, 6, 9,
18, 27, 36) were added along with 12 mg of internal standard in
separated reactions. The reactions were conducted at 60°C with
and without excess norbornene. All the experiments were stopped
at the 68% of conversion and HPLC analyses were performed. The
plot of the reaction is reported in Figure 6.
4
-[(1E,3E)-4-(3-Phenyl-1,2,4-oxadiazol-5-yl)buta-1,3-dien-1-yl]morpho-
line 11j, 1.68 g (99%), yellow crystals from methanol, m.p. 138–
À 1
1
139°C. IR: ν
1635 cm . H-NMR (DMSO) δ: 3.25 (m, 4H, morpho-
C=N
line); 3.63 (m, 4H, morpholine); 5.51 (t, 1H, J=12 Hz, CH=); 6.00 (d,
1
H, J=15 Hz, CH=); 7.08 (d, 1H, J=12 Hz, CH=); 7.53 (m, 4H, phenyl,
13
CH=); 7.98 (m, 2H, phenyl). C-NMR (DMSO) δ: 66.0; 97.7; 97.9;
27.2; 127.5; 129.4; 131.4; 146.9; 151.8; 167.7; 177.4. Anal. Calcd for
C H N O (283.33): C, 67.83; H, 6.05; N, 14.83. Found: C, 67.84; H,
1
1
6
17
3
2
6
.03; N, 14.85.
ChemistryOpen 2019, 8, 1209–1221
1219
© 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA